summary slide.png (119.72 kB)
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
media
posted on 2021-03-26, 16:23 authored by Adis journals on behalf of, Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, Susanne Sandgaard, Pia Holmgaard, Evan C. Frary, Niels EjskjaerArticle full text
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
